DDInter810 DDInter624
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Gefitinib {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is regulated by {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is upregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) upregulates {v} (Gene) AGL
AGL {u} (Gene) is downregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Gefitinib {u} (Compound) upregulates {v} (Gene) AGL
AGL {u} (Gene) regulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Gefitinib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Gefitinib (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Gefitinib (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Gefitinib (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Gefitinib (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Gefitinib (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is regulated by TBX2 (Gene) and TBX2 (Gene) is upregulated by Efavirenz (Compound)
Gefitinib (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Gefitinib (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is upregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Gefitinib (Compound) upregulates AGL (Gene) and AGL (Gene) is downregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Gefitinib (Compound) upregulates AGL (Gene) and AGL (Gene) regulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)